MOLCURE Inc. announced that it has entered into a multi-year strategic research agreement with Boehringer Ingelheim for the discovery of innovative antibody therapeutics for multiple targets using MOLCURE’s proprietary AI-driven platform technology.

Therapeutic monoclonal antibodies (mAbs) have become a cornerstone of modern medicine—especially in oncology, autoimmune, and infectious diseases. Millions of patients globally already benefit from mAb-based therapies, and many more stand to gain as new targets and indications are explored (1). Yet despite their success, the discovery and development of mAbs with traditional methods remains complex and time-intensive.

This collaboration aims to leverage the complementary strengths of both companies to unlock new possibilities in the discovery of antibody therapeutics. Traditional approaches to antibody discovery have explored only a fraction of the vast design space. The integration of AI into the discovery process is designed to enable broader, faster, and more efficient exploration and optimization of antibody candidates.

MOLCURE has developed a proprietary AI-driven platform centered around a large language model (LLM) specifically designed for antibody engineering. Leveraging its expertise in integrating LLMs into antibody discovery workflows, MOLCURE will work with Boehringer Ingelheim to combine high-throughput experimental data generated by them with a custom-tuned antibody LLM. This hybrid approach – combining wet-lab data with in silico modeling – is expected to enable the design of novel antibody sequences, including candidates that were previously difficult to identify using conventional methods.

“We are delighted that Boehringer Ingelheim has chosen MOLCURE as a partner in recognition of our AI technology’s ability to deliver strong results from limited data,” said Satoshi Tamaki, CEO and CSO of MOLCURE Inc. “We are excited to work alongside Boehringer Ingelheim’s scientists to further evolve our innovative AI-driven antibody discovery platform and make a significant contribution to their drug discovery programs. I hope that our partnership will lead to new treatments that improve the prognosis and quality of life for patients around the world.”

This partnership aligns with Boehringer Ingelheim’s ambition to deliver first-in-class therapies that transform the lives of patients. By combining complementary strengths in AI and biology, the two companies aspire to accelerate the development of next-generation antibody drugs.a